@article{2960c91fe26b4733afca4a7f9240ff38,
title = "Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: A Cancer and Leukemia Group B 59909 correlative science study",
abstract = "The proliferation index in mantle cell lymphoma (MCL) has not been validated in the context of aggressive therapy regimens in the rituximab era. We assessed Ki67 and PIM1 (a cell cycle-related gene upregulated in blastoid MCL) expression by immunohistochemistry in a phase II study Cancer and Leukemia Group B 59909 of aggressive chemotherapy and rituximab followed by autologous stem cell transplantation plus rituximab in untreated MCL patients <70 years of age. As a continuous variable or using a cutoff of 35\%, higher image analysis (IA Ki67, n = 52) was associated with shorter progression free survival (PFS) (P ≤ 0.030) and event free survival (EFS) (P ≤ 0.017). PIM1 expression (n = 50) was associated with PFS (P = 0.033) and EFS (P = 0.043). Bivariate Cox models showed IA Ki67 and PIM1 were independent of clinical factors. High Ki67 (>35\%) is an important independent prognostic marker in aggressively treated MCL in the rituximab era. PIM1 expression predicts poor outcome and, given its potential role as a therapeutic target, deserves further study.",
keywords = "Clinical trial, Ki67, Mantle cell lymphoma, PIM1, Prognosis, Transplant",
author = "Hsi, \{Eric D.\} and Jung, \{Sin Ho\} and Raymond Lai and Johnson, \{Jeffrey L.\} and Cook, \{James R.\} and Dan Jones and Sven Devos and Bruce Cheson and Damon, \{Lloyd E.\} and Jonathan Said",
note = "Funding Information: The authors acknowledge the CALGB Pathology Coordinating Office for their technical support. E. D. H. was supported by CA04919, S.-H. J. was supported by CA33601, R. L. was supported by CA016254, J. L. J. was supported by CA33601, J. R. C. was supported CA04919, D. J. was supported by CA105409, S. D. was supported by CA58348, B. D. C. was supported by CA77597, L. E. D. was supported by CA60138, J. S. was supported by CA58348. The research for CALGB 59909 was supported, in part, by grants from the National Cancer Institute (CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman) and to the CALGB Statistical Center (Stephen George, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Dana-Farber Cancer Institute, Boston, MA–Eric P. Winer, M.D., supported by CA32291. Dartmouth Medical School – Norris Cotton Cancer Center, Lebanon, NH–Marc S. Ernstoff, M.D., supported by CA04326. Georgetown University Medical Center, Washington, DC–Minetta C. Liu, M.D., supported by CA77597. Illinois Oncology Research Association, Peoria, IL–John W. Kugler, M.D., supported by CA35113. Mount Sinai School of Medicine, New York, NY–Lewis R. Silver-man, M.D., supported by CA04457. North Shore – Long Island Jewish Medical Center, Manhasset, NY– Daniel R Budman, M.D., supported by CA35279. State University of New York Upstate Medical University, Syracuse, NY–Stephen L. Graziano, M.D., supported by CA21060. The Ohio State University Medical Center, Columbus, OH–Clara D Bloomfield, M.D., supported by CA77658. University of California at San Diego, San Diego, CA–Joanne Mortimer, M.D., supported by CA11789. University of California at San Francisco, San Francisco, CA– Alan P. Venook, M.D., supported by CA60138. University of Chicago, Chicago, IL –Gini Fleming, M.D., supported by CA41287. University of North Carolina at Chapel Hill, Chapel Hill, NC–Thomas C. Shea, M.D., supported by CA47559. Vermont Cancer Center, Burlington, VT–Hyman B. Muss, M.D., supported by CA77406. Wake Forest University School of Medicine, Winston-Salem, NC–David D Hurd, M.D., supported by CA03927. Washington University School of Medicine, St. Louis, MO–Nancy Bartlett, M.D., supported by CA77440. Weill Medical College of Cornell University, New York, NY–Scott Wadler, M.D., supported by CA07968. Western Pennsylvania Cancer Institute, Pittsburgh, PA–Richard K. Shadduck, M.D.",
year = "2008",
doi = "10.1080/10428190802419640",
language = "English",
volume = "49",
pages = "2081--2090",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
number = "11",
}